Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DVT8O0
|
|||
| Drug Name |
ABP 654
|
|||
| Synonyms |
Ustekinumab biosimilar
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Plaque psoriasis [ICD-11: EA90.0; ICD-10: L40.0; ICD-9: 696] | Phase 3 | [1] | |
| Psoriatic arthritis [ICD-11: FA21; ICD-9: 696] | Phase 3 | [1] | ||
| Company |
Amgen
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04607980) A Phase 3, Multicenter, Randomized, Double-Blind Study Evaluating the Efficacy and Safety of ABP 654 Compared With Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Amgen | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.